Skip to content

The Effects of Sourness and Spicyness on Swallowing

Effects of Liquid Acidity and Capsaicinoids on Swallowing Function in Healthy Adults

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0011636
Enrollment
52
Registered
2026-02-24
Start date
2026-03-02
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Others(Have the subjects swallow 5 ml of plain water (pH 7) and 5 ml of acidic solutions of three acidities (pH 3, pH 4, pH 5) twice with an interval of up to 1 minute.) : Acidic solutions were prepar
Suntrup-Krüger et al., 2021).

Sponsors

Gyeongsang National University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Adults aged 20 to 65

Exclusion criteria

Exclusion criteria: 1) Current or past medical history of dysphagia (stroke, Parkinson's disease, multiple sclerosis, myopathy, progressive neuromuscular disease, etc.) 2) Moderate or severe heart, lung, or kidney disease (heart failure of NYHA class II or higher, COPD, ILD, chronic kidney disease of stage 2 or higher) 3) Diagnosed with asthma 4) History of allergy/hypersensitivity to citric acid or capsaicin 5) History of surgery or structural abnormalities in the oral cavity, pharynx, or larynx 6) Pregnant or lactating women 7) Current heartburn, diagnosis of Grade 2 or higher GERD (moderate symptoms with spontaneous but slow remission and mild interference with normal activity and sleep), or active esophagitis or bleeding from a gastric ulcer within the past 3 months 8) Current sore throat or respiratory symptoms (cough, dyspnea), or history of upper respiratory tract infection within the past 2 weeks 9) Current or past 2 weeks of any of the following: If taking the same medication: - Central nervous system depressants (Benzodiapenzines, opioids, antipsychotics, etc.) - Anticonvulsants - Antidepressants - Anticoagulants (Wafarin, NOACs, etc.) - Anticholinergics - ACE inhibitors 10) In addition, if the investigator determines that the medication is not appropriate for safety reasons (e.g., uncooperativeness, cognitive decline)

Design outcomes

Primary

MeasureTime frame
Activation onset time (sec) of the orbicularis oculi muscle;Activation start time (sec) of the masseter muscle;Activation start time (sec) of the submandibular muscle;Infrahyoid muscle activation onset time (sec);mean and standard deviation of activation (mV) of the orbicularis oculi muscle;activation duration (sec) of the orbicularis oculi muscle;mean and standard deviation of activity (mV) of the masseter muscle;activation duration (sec) of the masseter muscle;mean and standard deviation of activation (mV) of the submandibular muscle;activation duration (sec) of the submandibular muscle;Infrahyoid muscle mean and standard deviation of activation (mV);Infrahyoid muscle activation duration (sec)

Secondary

MeasureTime frame
Age, gender, underlying disease

Countries

Korea, Republic of

Contacts

Public ContactHayoung Byun

Gyeongsang National University Hospital

minusbyun@naver.com+82-55-750-8256

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Mar 14, 2026